Our biotech columnist live-blogged the outside panel of cancer experts convened by the FDA reviews Cell Therapeutics' lymphoma drug pixantrone on Monday; read on to review the action.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Stocks with insider trader activity include LPNT, PATK and CTIC